Search

Your search keyword '"A, Boehnlein"' showing total 18 results
Start Over Author "A, Boehnlein" Journal fertility and sterility
18 results on '"A, Boehnlein"'

1. A deep learning framework outperforms embryologists in selecting day 5 euploid blastocysts with the highest implantation potential

Author

Leslie B. Ramirez, Charles L. Bormann, Lynn M. Boehnlein, Prudhvi Thirumalaraju, Manoj Kumar Kanakasabapathy, Pragati Bhowmick, Raghav Gupta, Carol Lynn Curchoe, Irene Dimitriadis, Eduardo Hariton, Rohan Pooniwala, Sarah T. Rice, Irene Souter, Hadi Shafiee, and Jason E. Swain

Subjects
Reproductive Medicine, business.industry, Computer science, Deep learning, Obstetrics and Gynecology, Artificial intelligence, business, Machine learning, computer.software_genre, computer
Published
2019

2. A deep learning framework outperforms embryologists in selecting day 5 euploid blastocysts with the highest implantation potential

Author

Hariton, Eduardo, primary, Dimitriadis, Irene, additional, Kanakasabapathy, Manoj Kumar, additional, Thirumalaraju, Prudhvi, additional, Gupta, Raghav, additional, Pooniwala, Rohan, additional, Souter, Irene, additional, Rice, Sarah T., additional, Bhowmick, Pragati, additional, Ramirez, Leslie B., additional, Curchoe, Carol Lynn, additional, Swain, Jason E., additional, Boehnlein, Lynn M., additional, Bormann, Charles L., additional, and Shafiee, Hadi, additional

Published
2019
Full Text
View/download PDF

4. Antimüllerian hormone as a predictor of good-quality supernumerary blastocyst cryopreservation among women with levels1 ng/mL versus 1-4 ng/mL

Author

Thomas B. Pool, Lynn M. Boehnlein, Kate C. Odenwald, Jason E. Swain, Roxanne B. Summers-Colquitt, Dan I. Lebovic, Jeffrey M. Jones, Shahryar K. Kavoussi, and Mary J. Lindstrom

Subjects
Anti-Mullerian Hormone, Time Factors, endocrine system diseases, Pregnancy Rate, Oocyte Retrieval, Cryopreservation, Embryo Culture Techniques, antimüllerian hormone, MicroDose, Pregnancy, Obstetrics and Gynaecology, AMH, media_common, Obstetrics and Gynecology, Texas, female genital diseases and pregnancy complications, medicine.anatomical_structure, Treatment Outcome, embryonic structures, Female, hormones, hormone substitutes, and hormone antagonists, Maternal Age, Agonist, Adult, medicine.medical_specialty, endocrine system, medicine.drug_class, media_common.quotation_subject, Fertility, Fertilization in Vitro, freezing, Andrology, Wisconsin, Ovulation Induction, medicine, Humans, Supernumerary, Blastocyst, Retrospective Studies, Gynecology, business.industry, urogenital system, Retrospective cohort study, Fertility Agents, Female, Embryo Transfer, Reproductive Medicine, Infertility, business, Biomarkers, Hormone
Abstract

ObjectiveTo determine whether antimüllerian hormone (AMH) levels predict the availability of good-quality supernumerary blastocysts for cryopreservation.DesignRetrospective study.SettingTwo fertility centers.Patient(s)First fresh IVF cycles (n = 247) grouped as follows: 40 women

Published
2015

6. Antimüllerian hormone as a predictor of good quality supernumerary blastocyst cryopreservation

Author

Roxanne B. Summers-Colquitt, Jeffrey M. Jones, Mary J. Lindstrom, Lynn M. Boehnlein, Shahryar K. Kavoussi, Thomas B. Pool, Jason E. Swain, Kate C. Odenwald, and Dan I. Lebovic

Subjects
Gynecology, Antimullerian Hormone, medicine.medical_specialty, medicine.anatomical_structure, Reproductive Medicine, business.industry, Obstetrics and Gynecology, Medicine, Supernumerary, Blastocyst, business, Cryopreservation
Published
2015

15. Evaluation of the shelf life of G2.2 medium

Author

Jeffrey M. Jones, R. Ricketts, E. Schleinz, and Lynn M. Boehnlein

Subjects
Oceanography, Reproductive Medicine, Obstetrics and Gynecology, Environmental science, Shelf life
Published
2001

16. Diagnosis-specific serum 17β-estradiol (E2) upper limits for treatment with menotropins using a 125I direct E2 assay

Author

Ian H. Carlson, Ray V. Haning, Lynn M. Boehnlein, William J. Zweibel, and Donna L. Kuzma

Subjects
medicine.medical_specialty, Menotropins, Time Factors, medicine.drug_class, media_common.quotation_subject, medicine.medical_treatment, Radioimmunoassay, Ovarian hyperstimulation syndrome, Ovary, Biology, Chorionic Gonadotropin, Models, Biological, Iodine Radioisotopes, Ovulation Induction, Pregnancy, Internal medicine, medicine, Humans, Amenorrhea, Ovulation, media_common, Chromatography, Estradiol, Obstetrics and Gynecology, medicine.disease, Polycystic ovary, Endocrinology, medicine.anatomical_structure, Reproductive Medicine, Estrogen, Female, Ovulation induction, Infertility, Female, Hypothalamic Diseases, Polycystic Ovary Syndrome
Abstract

Statistical evaluation of 133 cycles of induction of ovulation using generalized linear models demonstrated that the occurrence and severity of ovarian hyperstimulation was influenced by the serum 17 beta-estradiol (E2) concentration (P less than 0.001), conception (P less than 0.001), and the endocrinologic diagnosis, polycystic ovary syndrome (PCO) or hypothalamic amenorrhea (HA) (P less than 0.01). When menotropins were administered between 5:00 P.M. and 8:00 P.M. and blood was drawn at 8:00 A.M., an upper limit for serum E2 in patients with HA of 2417 pg/ml or an upper limit for patients with PCO of 3778 pg/ml gave an approximate 5% risk of severe ovarian hyperstimulation in conception cycles and a 1.3% risk of severe hyperstimulation in nonconception cycles. Comparison of our E2 radioimmunoassay involving extraction and chromatography to the Pantex immunodirect Estradiol 125I kit (Pantex, Santa Monica, CA) demonstrated no detectable systematic error, allowing the use of these limits with either assay. The ovulating injection of human chorionic gonadotropin was given at 5:00 P.M. to 8:00 P.M. on the evening of blood drawing as soon as the first follicle reached an average diameter of 14 mm or greater. The ultrasound parameters allow the chance of pregnancy to be optimized and the chance of multiple gestation to be minimized. Serum E2 monitoring indicates when the risk of ovarian hyperstimulation is too great for human chorionic gonadotropin to be given.

Published
1984

17. Diagnosis-specific serum 17β-estradiol (E2) upper limits for treatment with menotropins using a 125I direct E2assay**Supported in part by the Pantex Corporation, Santa Monica, California.

Author

Haning, Ray V., Boehnlein, Lynn M., Carlson, Ian H., Kuzma, Donna L., and Zweibel, William J.

Abstract

Statistical evaluation of 133 cycles of induction of ovulation using generalized linear models demonstrated that the occurrence and severity of ovarian hyperstimulation was influenced by the serum 17β-estradiol (E2) concentration (P<0. 001), conception (P<0.001), and the endocrinologic diagnosis, polycystic ovary syndrome (PCO) or hypothalamic amenorrhea (HA) (P<0.01). When menotropins were administered between 5:00 P.M. and 8:00 P.M. and blood was drawn at 8:00 A.M., an upper limit for serum E2in patients with HA of 2417 pg/ml or an upper limit for patients with PCO of 3778 pg/ml gave an approximate 5% risk of severe ovarian hyperstimulation in conception cycles and a 1.3% risk of severe hyperstimulation in nonconception cycles. Comparison of our E2radioimmunoassay involving extraction and chromatography to the Pantex immunodirect Estradiol 125I kit (Pantex, Santa Monica, CA) demonstrated no detectable systematic error, allowing the use of these limits with either assay. The ovulating injection of human chorionic gonadotropin was given at 5:00 P.M. to 8:00 P.M. on the evening of blood drawing as soon as the first follicle reached an average diameter of 14mm or greater. The ultrasound parameters allow the chance of pregnancy to be optimized and the chance of multiple gestation to be minimized. Serum E2monitoring indicates when the risk of ovarian hyperstimulation is too great for human chorionic gonadotropin to be given.

Published
1984
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results